ReportWire

Tag: Morehouse School of Medicine

  • A Diagnosis, A Decade, and the Weight of Stigma

    [ad_1]

    On a warm Florida night in May 2013, Christopher “Super” Green learned he was HIV-positive.

    “I got my diagnosis on a date, actually,” he said. “I was dating a guy, and we wanted to be intimate. He was studying public health, so we went to a clinic together.”

    The result stunned him. Just months earlier, he had tested negative. “I remember feeling like my world had ended,” Green said. “At this point, I felt like my life was over. No one was going to love me. This is it. Get ready. I have three years to live.”

    Christopher Green, 34, has been on antiretroviral medication since being diagnosed with HIV a decade ago. The medication provides a healthy life and suppresses the virus, so he is undetectable and cannot transmit it. Photo by Dyana Bagby/The Atlanta Voice

    Those early days were marked by fear and shame. Shame made him feel isolated, unwanted, untouchable. But Green’s best friend, T.J., promised to stand by him. That support, combined with meeting J.J.—a young, Black case manager who spoke his language and understood his experiences—shifted everything. J.J. inspired Green to pursue public health himself.

    Ten years later, Green is thriving. He works as a lead prevention navigator at Here’s to Life, a nonprofit in Atlanta’s West End serving men with HIV and substance use disorders. He tells his story openly because silence, he said, only fuels stigma.

    “For many people, the stigma is more dangerous than HIV itself,” Green explained. “It keeps people from getting tested, starting treatment, or reaching out for support.”

    Green’s story mirrors a larger crisis: HIV continues to disproportionately affect Black communities in the South, where systemic inequities drive persistent disparities.

    Structural Inequities

    Nationwide, more than 1.13 million people were living with HIV in 2023, according to AIDSVu, a project of Emory University. Those aged 55–64 made up the largest group, 26%. Black individuals accounted for 39% of people living with HIV—despite being just 12% of the U.S. population. The prevalence rate among Black Americans was seven times higher than among white Americans.

    The disparities start with prevention. In 2023, Black Americans made up 38% of new HIV diagnoses but just 14% of those eligible for PrEP, a highly effective prevention pill.

    “These systemic inequities are the main driver,” said Rashad Burgess, vice president of corporate responsibility at Gilead Sciences. “We’ve known this for a long time, and it’s still true today.”

    Rashad Burgess of Gilead Sciences said systemic health inequities are the primary driver of HIV disparities and the reason HIV disproportionately impacts Black communities. Photo courtesy Gilead Sciences 

    Atlanta is one of the nation’s HIV hotspots, with Fulton County reporting that Black residents account for more than 60% of new diagnoses, though they make up roughly 40% of the population. AIDSVu maps show the hardest-hit neighborhoods concentrated in southwest Atlanta and along the I-20 corridor, areas shaped by housing instability, limited transportation, and scarce access to culturally competent healthcare.

    “Having the ability to get a ride to a doctor’s office is key,” Burgess said. “If you’re unstably housed, it’s hard to stay on medications. And if you’re not virologically suppressed, you’re more likely to transmit the virus and your health outcomes decline.”

    Gaps in Prevention

    Access to PrEP remains one of the biggest gaps. Even when Black patients are engaged in healthcare, Burgess said, they are less likely to be offered PrEP due to provider bias.

    “What we find to be really successful are systems that routinize HIV screening,” he said. “That way, people know their status and, if negative, can be offered PrEP as a natural next step.”

    Longtime Atlanta activist Daniel Driffin said too many providers still refer patients to specialty clinics instead of prescribing PrEP themselves. Combined with high uninsured rates and Georgia’s refusal to expand Medicaid, many fall through the cracks.

    “We’re waiting for people to learn they’re living with HIV before we intervene,” Driffin said. “That’s a horrible place to be in public health.”

    Driffin and other activists launched a community-led prevention model to address the gap. Over 60 days, more than 150 participants helped design a program focused on three pillars: robust HIV testing, a pooled “people’s purse” to fund prevention efforts, and culturally resonant messaging.

    “We create a hand-holding situation until that person begins care,” Driffin said. “Community-led solutions alongside public health oversight ensure that people aren’t being forgotten.”

    Progress and Threats

    Medical advances have made HIV manageable. In 2023, 82.8% of newly diagnosed individuals were linked to care, 76.3% of people living with diagnosed HIV received care, and 67.2% achieved viral suppression.

    “You can live a normal life, have a normal lifespan, with your virus being managed by therapy,” Burgess said.

    But progress is fragile. More than 80% of CDC prevention funding supports state and local health departments through the federal Ending the HIV Epidemic initiative. Proposed cuts of nearly $1.5 billion to Medicaid and CDC budgets could erode years of gains, leading to more infections nationwide.

    The Weight of Stigma

    Even with medicine and prevention tools, stigma remains the hardest barrier to break, particularly in the South.

    “As a matter of fact, many argue stigma is the number one barrier,” Burgess said. “It impacts whether people access PrEP, whether they seek treatment, and whether they’re diagnosed late or with AIDS.”

    To shift perceptions, Gilead invests in campaigns featuring trusted voices—from faith leaders to barbershops to celebrities like Tamar Braxton, who has publicly shared her use of PrEP. Partnerships with Morehouse School of Medicine extend outreach to rural Georgia.

    “We have to normalize HIV prevention and care as part of overall wellness,” Burgess said. “That means visual representation, trusted messengers, and community-driven dialogue.”

    For Green, that mission is personal. Each time he shares his story, he chips away at the silence that once left him isolated.

    “I learned what care looks like from another Black man because he knew how to relate to me, how to pour into me what I needed as opposed to giving me just clinical information,” Green said. 

    “We often talk about the social determinants of health within public health spaces, such as housing, employment, and access to a phone. But we can’t leave out the most important thing, and that is the person and meeting them where they are.” 

    [ad_2]

    Dyana Bagby

    Source link

  • Merck’s Dr. Adrelia Allen emphasizes need for clinical trial diversity, especially for African Americans

    Merck’s Dr. Adrelia Allen emphasizes need for clinical trial diversity, especially for African Americans

    [ad_1]

    NEW ORLEANS – While the ESSENCE Festival of Culture is known for fun times, great food, and link-ups with friends. However, it is a time for poignant conversation. Dr. Adrelia Allen is the Executive Director of Clinical Trial Patient Diversity at Merck, Inc. Merck is a global biopharmaceutical company. Before she spoke at the Global Black Economic Forum, Allen discussed how the lack of representation in the research of new treatments can impact our lives.

    First and foremost, clinical trials are research studies that test a medical, surgical, or behavioral intervention in people. These trials are the primary way that researchers determine if a new form of treatment or prevention, such as a new drug, diet, or medical device (for example, a pacemaker), is safe and effective in people.

    “We know that there are differences in how drugs work in different races,” Allen explained. “And for African Americans, knowing that we have the highest mortality of many diseases and cancers, we cannot wait. So it was definitely imperative for Merck to be here. And when we think about who’s attending ESSENCE, and knowing that [the audience is largely] Black women. When you educate a man, you educate an individual. But when you educate a woman, you educate the entire community.”

    How does historical traumas affect participation in clinical trials?

    According to a 2021 study by Johns Hopkins Medicine,  75% of research participants are White. Even though White Americans make up 60% of the United States population. By comparison, 8% of research participants are African-American/Black. Currently,  African-American/Black people are 13% of people in the U.S. There are a lot of historical prejudices, and those traumas do get passed down. Reports and those stories were amplified during the COVID-19 era, when people would bring up the Tuskegee experiment relative to the vaccine. 

    Allen acknowledged the existence of those traumas. However, there is no solution that directly fits all experiences and conditions.  Most Americans are distrustful of medicine. This is not a Black problem. COVID-19 and the anti-vax sentiment that we all ran up against to tell us enough that it’s not about the skin we’re in. it’s about the conditions, the systems, and the processes of care that failed to speak to the wounds.

    Dr. Adrelia Allen, the Executive Director of Clinical Trial Patient Diversity at Merck, Inc., poses for photographs outside the Ernest N. Morial Convention Center during the 2024 ESSENCE Festival of Culture on Saturday, July 6, 2024 in New Orleans, Louisiana. (Photo: Itoro N. Umontuen/The Atlanta Voice)

    She described a moment in which her father, while being diagnosed with prostate cancer, refused to take an MRI. Why? Because it was a trigger for him because of the Tuskegee experiment. He believed that he would be treated as a guinea pig. But, Allen says, the key is building trust.

    “Educating and making sure that we’re talking in communities working with trusted voices, because we can’t go in and simply start talking,” Allen explains. “Helping them understand so that they can be the relay for their communities and talking about clinical trials and in that means we are, keeping patients at the center of what we’re doing. And, we make sure we have community advisory boards that we bring and share recruitment materials, protocols, even procedures that are involved with the clinical trial.” 

    Other Barriers to Entry

    Trust is also the vehicle that allows for the doctor-patient relationship to flourish. The doctors will know what trials will be relevant as long as the patient is willing to disclose family histories and so on.

    In addition to race, disability and socioeconomic status are factors that play a role in lack of participation. To that end, Congress has passed the Diverse and Equitable Participation in Clinical Trials Act (also known as the DEPICT ACT) in 2022. Allen says the Federal Drug Administration’s guidance is pending. However, she’s looking forward to building Merck’s action plans. 

    Allen says Merck is working to operate clinical trials at the four historically Black medical schools. Included is Morehouse School of Medicine in Atlanta. These trials will be conducted by investigators and managers of color with participants from underrepresented populations. Additionally, Allen says Merck is also removing financial barriers to reimburse out-of-pocket travel costs for trial participants and providing a solution to ease transportation barriers.

    “Although the finalization of the FDA Diversity Action Plan guidance is pending, we are working across our clinical trial sites to implement mandatory, multi-pronged diversity action plans for all late-stage clinical trials,” Allen said. “We are taking concrete steps to help historically underrepresented communities access our clinical trials.”

    What’s Next

    In the end, every medicine that resides in the medicine cabinet, there must be more African-Americans to ensure that drug is going to be safe for us. 

    “We want to be a part of that,” Allen said while describing the clinical trial process. “The scientific medical innovations that are occurring today are the differences between life and death. Having access to that information is powerful, and we want to have that information before having to make the critical decision.”

    [ad_2]

    Itoro N. Umontuen

    Source link

  • Lupus Awareness Month: Georgia Chapter of Lupus Foundation supports those affected by the disease

    Lupus Awareness Month: Georgia Chapter of Lupus Foundation supports those affected by the disease

    [ad_1]

    Lupus is an autoimmune disease that affects thousands of individuals across the country. It can impact multiple parts of the body and cause severe internal damage. There isn’t a cure for this disease, and it imposes a significant emotional and financial toll on family members of people with Lupus. The Lupus Foundation of America (LFA) Georgia Chapter supports everyone affected by this issue. The organization offers assistance to those in need through various channels. May is Lupus Awareness Month, and the organization has planned activities for the rest of the month to allow locals to show their support for the Lupus community.

    “We should all care about this because anybody can get lupus. We should serve those who need to be served, and lupus is a very underserved population,” said Teri Emond, President and CEO of the Lupus Foundation of America, Georgia Chapter.

    May is Lupus Awareness Month background template. Holiday concept.

    The Lupus Foundation of America Georgia Chapter has been serving the community since 1978. Through advocacy, fundraising, and research, the organization has provided support to those dealing with the disease and their family members. In observance of Lupus Awareness Month in May, the chapter organized several events. On Saturday, May 18, the chapter hosted a Lupus walk in Augusta, GA, where Morehouse School of Medicine presented the latest research on Lupus. Additionally, Georgia chapter members traveled to Washington, D.C., from May 19 to May 21 to advocate for more funding for Lupus research at the national advocacy summit.

    [ad_2]

    Clayton Gutzmore

    Source link

  • Morehouse School of Medicine and Families First join forces to deliver accessible mental health care for youth

    Morehouse School of Medicine and Families First join forces to deliver accessible mental health care for youth

    [ad_1]

    Photo by Allison Joyner/The Atlanta Voice

    According to the Work Health Organization (WHO), one in seven 10-19-year-olds experience a mental disorder, including depression and anxiety, with suicide being the fourth leading cause of death for 15-29 year-olds. 

    Morehouse School of Medicine (MSM), along with mental health nonprofit Families First, is helping to bring accessible mental health care for young people with its new child and adolescent psychiatry (CAP) clinic. 

    MSM behavioral health clinicians will be available to see patients on Tuesdays from 9 a.m. to 1 p.m. at the Families First facility on Joseph E. Lowery Blvd, where CAP fellows and psychiatry residents will evaluate and treat mental health conditions in youth up to age 21. 

    [ad_2]

    Allison Joyner

    Source link